ctDNA Accurately Detects BRAF Mutations in Advanced Melanoma, Study Finds

Source: AJMC, March 2022

A new report shows better than 80% concordance between liquid biopsy and tissue biopsy.

Liquid biopsy and analysis of circulating tumor DNA (ctDNA) is a viable option for determining the presence of BRAF mutations in patients with advanced melanoma, according to a new report based on real-world data.

These findings show that ctDNA analysis is feasible in routine clinical practice, and not just in a clinical trial setting. They were published in Cancers.

The study authors, of the Medical University of Warsaw, in Poland, explained that patients with advanced melanoma tend to have unsatisfactory results with chemotherapy. However, the development of BRAF inhibitors and MEK inhibitors has substantially changed the treatment landscape for these patients. These developments have also made it essential to test patients for mutations, they added.